Solid Tumor Testing in Canada Trends and Forecast
The future of the solid tumor testing market in Canada looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets. The global solid tumor testing market is expected to reach an estimated $1641.7 billion by 2031 with a CAGR of 3.5% from 2025 to 2031. The solid tumor testing market in Canada is also forecasted to witness strong growth over the forecast period. The major drivers for this market are an increase in the utilization of supplements and steroids and an increase in unhealthy habits, such as smoking and alcohol consumption.
• Lucintel forecasts that, within the application category, melanoma is expected to witness the highest growth over the forecast period due to the growing incidence of skin tumors and related conditions globally.
• Within the end use category, the hospital is expected to witness the highest growth due to the rising incidence of tumors and chronic diseases.
Emerging Trends in the Solid Tumor Testing Market in Canada
Canada’s solid tumor testing market continues to develop due to advancements in technology and the growing need for tailored cancer treatment solutions. These factors are driving improvements in cancer screening, precision medicine, and streamlined diagnostics. As the industry moves toward more targeted therapies, innovations such as liquid biopsy, next-generation sequencing (NGS), artificial intelligence (AI) in pathology, companion diagnostics, and public-private collaborations are transforming oncology diagnostics. These advancements increase diagnostic precision, expand the availability of modernized testing, and improve health outcomes, positioning Canada as a leader in precision oncology.
• Growing Acceptance of Liquid Biopsies: Liquid biopsy is gaining significance as a cancer diagnostic tool in Canada due to its non-invasive ability to detect circulating tumor DNA (ctDNA) from blood samples. This method enables early cancer detection, real-time monitoring of treatment effectiveness, and disease progression tracking without the need for surgical biopsies. As healthcare professionals and researchers recognize the benefits of liquid biopsy, its adoption is increasing in clinics and diagnostic centers. The expanded use of liquid biopsies enhances patient comfort, improves compliance, and allows for timely medical intervention, making it a crucial tool in precision medicine.
• Wider Adoption of Next-Generation Sequencing (NGS) Technology: Next-generation sequencing (NGS) is significantly impacting the solid tumor testing process in Canada by enabling comprehensive genomic profiling of tumors. This technology allows for the simultaneous analysis of multiple genetic mutations, providing critical insights into cancer’s molecular characteristics. The decreasing cost of sequencing and the increased availability of NGS in research and clinical settings have led to its widespread use. By helping oncologists make more informed therapeutic decisions, NGS is driving the shift toward precision medicine and improving the personalization of cancer treatment.
• AI’s Role in Revolutionizing Cancer Diagnostics: AI is transforming cancer diagnostics in Canada by enhancing the speed and accuracy of pathology assessments. AI-powered algorithms assist pathologists in analyzing digital pathology images and detecting subtle patterns that may be overlooked by human specialists. This technology helps address staffing shortages in pathology departments and accelerates the delivery of test results. The integration of AI in oncology diagnostics reduces diagnostic errors, streamlines workflows, and improves overall efficiency in cancer detection and treatment planning.
• Expansion of Companion Diagnostics for Targeted Treatments: Companion diagnostic tests are playing a vital role in the advancement of precision oncology in Canada. These tests help identify biomarkers that determine a patient’s likelihood of responding to specific therapies. As pharmaceutical companies continue to develop targeted cancer treatments, the demand for companion diagnostics is increasing. Collaborations between diagnostic companies and drug manufacturers are accelerating the development and commercialization of precision medicine therapies. These partnerships enhance treatment effectiveness and reduce side effects, improving patient outcomes.
• Strengthening Public-Private Partnerships in Cancer Research: Canada’s solid tumor testing market is advancing due to collaborations between the public and private sectors. Government agencies, academic institutions, and corporations are working together to develop and commercialize new cancer diagnostics. These partnerships support large-scale genomic studies, expand clinical trial opportunities, and facilitate the introduction of innovative testing technologies. By fostering collaboration among key stakeholders, these initiatives enhance access to advanced diagnostic solutions and improve cancer detection and treatment outcomes.
Advancements in technology and the global shift toward personalized medicine are reshaping the solid tumor testing market in Canada. Trends such as the adoption of liquid biopsies, NGS, AI-driven diagnostics, and strategic partnerships are improving the accuracy, efficiency, and accessibility of cancer testing. These developments position Canada at the forefront of cancer care innovation, leading to better patient outcomes. As these trends continue to evolve, they will significantly influence the future of cancer diagnostics and treatment in Canada.
Recent Developments in the Solid Tumor Testing Market in Canada
With the increasing use of solid tumor testing, Canada has made significant strides in improving the accuracy and efficiency of cancer diagnosis. Key developments include the expansion of liquid biopsy, increased adoption of next-generation sequencing (NGS), integration of artificial intelligence (AI) in pathology, growth in companion diagnostics, and increased government funding for cancer research. These advancements are accelerating the development of personalized cancer treatment plans, reducing diagnostic delays, and enhancing oncology care. Together, these factors are strengthening cancer diagnostics in Canada, leading to better patient outcomes and improved clinical decision-making.
• Continued Expansion of Liquid Biopsy in Clinical Practice: Liquid biopsy is being widely adopted in Canada as a non-invasive and highly effective tool for detecting and monitoring tumors. Healthcare providers are incorporating liquid biopsy tests into routine clinical practice to enable real-time assessment of treatment response. Ongoing regulatory approvals and clinical research are driving further adoption, making this technology more accessible to patients. Liquid biopsy’s ability to detect minimal residual disease (MRD) and tumor-associated mutations without invasive procedures is transforming cancer diagnostics, enabling earlier interventions and more targeted treatments.
• Accelerated Adoption of Next-Generation Sequencing (NGS): The increased use of NGS is revolutionizing solid tumor diagnostics and treatment in Canada. Advances in NGS technology have reduced costs and improved turnaround times, making it a critical tool in oncology diagnostics. Hospitals and research centers are leveraging NGS to detect genetic mutations in tumors, allowing for more precise treatment decisions. Government and private-sector investments in genomic research programs are further promoting the integration of NGS into precision medicine. Enhanced tumor profiling through NGS is increasing diagnostic accuracy and supporting the development of more effective cancer therapies.
• AI-Driven Improvements in Cancer Detection: Canadian hospitals and diagnostic laboratories are integrating AI technology to optimize cancer detection. AI-powered diagnostic tools help pathologists analyze medical images with greater accuracy and efficiency, reducing diagnostic variability and improving early cancer detection. This development is particularly beneficial in regions facing a shortage of specialized medical professionals. AI’s role in oncology diagnostics is standardizing assessments, improving pathology workflows, and reducing turnaround times. As AI technology continues to advance, it is expected to further enhance diagnostic precision and support more timely treatment decisions.
• Increased Use of Companion Diagnostics for Precision Medicine: Companion diagnostics are becoming increasingly important in Canadian cancer care, helping match patients with the most effective targeted therapies. Pharmaceutical companies and diagnostic firms are collaborating to co-develop cancer drugs and companion tests, expediting regulatory approvals and ensuring that therapies are tailored to the right patients. The expansion of companion diagnostics is driving the shift toward precision oncology, improving treatment outcomes, reducing adverse effects, and increasing the effectiveness of cancer therapies. As the number of targeted treatments grows, the demand for companion diagnostics continues to rise.
• Greater Investment in Cancer Research from the Public and Private Sectors: Cancer research in Canada is receiving increased funding from both government initiatives and private organizations. Programs such as the Canadian Cancer Research Alliance and genomics-focused initiatives are accelerating the development of innovative testing methodologies. Resources are being allocated to expand clinical trials, improve laboratory infrastructure, and integrate new diagnostic technologies into healthcare settings. This investment is fostering innovation in solid tumor testing, increasing patient access to cutting-edge diagnostics, and reinforcing Canada’s position as a leader in global oncology research.
Recent developments in Canada’s solid tumor testing market are significantly enhancing the accuracy, efficiency, and accessibility of cancer diagnostics. The adoption of liquid biopsy, NGS, AI in pathology, companion diagnostics, and increased research funding is improving early cancer detection and enabling more precise treatment approaches. These advancements are streamlining cancer diagnosis, expediting treatment decisions, and strengthening Canada’s healthcare system. As these innovations continue to progress, they will play a crucial role in shaping the future of oncology, leading to improved cancer care and better patient outcomes.
Strategic Growth Opportunities for Solid Tumor Testing Market in Canada
The solid tumor testing market in Canada is experiencing rapid advancements due to technological innovations and the rising demand for precision medicine. Key applications such as liquid biopsy, next-generation sequencing (NGS), artificial intelligence (AI) in diagnostics, companion diagnostics, and biomarker-based early detection are opening new growth avenues. These opportunities enhance the accuracy and efficiency of cancer detection and treatment, improving patient outcomes. As the healthcare industry shifts toward more targeted therapies, stakeholders—including diagnostic companies, healthcare providers, and research institutions—can leverage these opportunities to drive innovation, expand market reach, and establish Canada as a leader in oncology diagnostics.
• Expansion of Liquid Biopsy for Early Cancer Detection: Liquid biopsy is gaining traction as a non-invasive diagnostic tool capable of detecting cancer at earlier stages. Unlike traditional biopsies, this method analyzes circulating tumor DNA (ctDNA) from blood samples, providing real-time insights into tumor progression and treatment response. The increasing adoption of liquid biopsy in routine cancer screening can significantly improve early detection rates, allowing for timely intervention. Investments in refining liquid biopsy technology and expanding its clinical applications will enhance diagnostic accuracy, increase patient accessibility, and position Canada as a hub for advanced cancer detection methodologies.
• Integration of Next-Generation Sequencing (NGS) for Comprehensive Tumor Profiling: The adoption of NGS is transforming solid tumor testing by enabling comprehensive genomic profiling of tumors. This technology allows for the simultaneous analysis of multiple genetic alterations, offering valuable insights for personalized treatment planning. As NGS becomes more cost-effective and widely available, its use in hospitals and diagnostic centers is expected to grow. Expanding reimbursement policies and increasing awareness among healthcare professionals can further drive adoption. NGS empowers oncologists to tailor therapies based on a tumor’s genetic profile, improving treatment outcomes and reducing the likelihood of ineffective therapies.
• Advancing AI-Powered Diagnostics for Faster and More Accurate Results: Artificial intelligence (AI) is playing a crucial role in enhancing cancer diagnostics by improving the speed and accuracy of pathology assessments. AI-powered algorithms assist pathologists in analyzing medical images and identifying cancerous patterns with high precision. This technology addresses the growing demand for efficient diagnostic solutions, especially in regions with a shortage of specialized professionals. The integration of AI in diagnostic workflows not only reduces variability in cancer detection but also expedites clinical decision-making. Expanding AI adoption in Canadian oncology laboratories can improve operational efficiency, reduce diagnostic errors, and enhance patient outcomes.
• Growth of Companion Diagnostics for Targeted Therapy Selection: Companion diagnostics are essential for identifying patients who are most likely to respond to specific cancer treatments. As pharmaceutical companies develop more targeted therapies, the need for companion diagnostic tests is rising. Collaborations between drug manufacturers and diagnostic companies can accelerate the availability of personalized medicine solutions in Canada. By integrating companion diagnostics into standard oncology practices, healthcare providers can optimize treatment selection, minimize adverse effects, and improve therapy success rates. The growing regulatory support for precision oncology further strengthens this opportunity, making Canada a prime market for innovative diagnostic solutions.
• Expansion of Biomarker-Based Early Detection Programs: The development of biomarker-based testing is revolutionizing early cancer detection by identifying molecular signatures associated with various tumor types. Advancements in biomarker discovery and validation are driving the integration of these tests into routine cancer screening programs. Increased investment in biomarker research, coupled with government initiatives promoting early cancer detection, can expand the accessibility of these tests across healthcare settings. By incorporating biomarker-driven diagnostics into preventive care strategies, Canada can enhance early intervention efforts, reduce healthcare costs, and improve survival rates for cancer patients.
The strategic growth opportunities in Canada’s solid tumor testing market are driving advancements in early cancer detection, personalized treatment, and diagnostic efficiency. Expanding applications in liquid biopsy, NGS, AI-powered diagnostics, companion diagnostics, and biomarker-based testing are shaping the future of oncology care. These innovations enhance precision medicine, improve patient outcomes, and strengthen Canada’s position as a leader in advanced cancer diagnostics. As stakeholders capitalize on these opportunities, the solid tumor testing market will continue to evolve, driving further innovation and accessibility in cancer care.
Solid Tumor Testing Market in Canada Driver and Challenges
The solid tumor testing market in Canada is shaped by a combination of technological advancements, economic factors, and regulatory policies. Key drivers include the growing demand for precision medicine, advancements in genomic sequencing, increased adoption of liquid biopsy, government funding for cancer research, and AI-driven innovations in diagnostics. However, the industry also faces challenges such as high costs associated with advanced testing, regulatory complexities, and a shortage of specialized healthcare professionals. Understanding these drivers and challenges is crucial for stakeholders aiming to navigate the evolving oncology diagnostics landscape and enhance the accessibility and efficiency of cancer testing.
The factors responsible for driving the solid tumor testing market in Canada include:
• Rising Demand for Precision Medicine: The shift toward personalized cancer treatment is a significant driver of the solid tumor testing market. Precision medicine relies on molecular profiling to tailor therapies based on a tumor’s genetic characteristics, improving treatment efficacy. The increasing prevalence of targeted therapies has fueled demand for advanced diagnostic tools, including NGS and companion diagnostics. As healthcare providers and pharmaceutical companies focus on individualized treatment strategies, precision medicine is expected to drive sustained growth in the tumor testing market, enabling better patient outcomes and optimizing healthcare resources.
• Advancements in Genomic Sequencing Technologies: Next-generation sequencing (NGS) is revolutionizing cancer diagnostics by allowing for in-depth genomic analysis of solid tumors. The decreasing cost of sequencing, coupled with improved efficiency, has expanded its adoption in clinical and research settings. As NGS technologies continue to evolve, they enable more precise cancer diagnostics, facilitate early detection, and support the development of targeted therapies. The integration of NGS into routine cancer care enhances treatment decision-making and accelerates the shift toward precision oncology, making it a crucial growth driver in the Canadian market.
• Increased Adoption of Liquid Biopsy for Non-Invasive Testing: Liquid biopsy is emerging as a transformative technology for solid tumor testing, offering a non-invasive alternative to traditional biopsies. This technique enables real-time monitoring of tumor evolution and treatment response, improving patient management. With ongoing clinical research validating its efficacy, liquid biopsy is gaining regulatory approvals and broader acceptance in oncology care. As adoption rates rise, liquid biopsy is expected to drive market growth by providing accessible, cost-effective, and less invasive cancer detection and monitoring options.
• Government Investments in Cancer Research and Diagnostics: The Canadian government is actively funding cancer research initiatives to enhance diagnostic capabilities and promote early detection programs. Public-private partnerships are fostering innovation in genomic research, AI-driven diagnostics, and biomarker discovery. Increased investment in research infrastructure and clinical trials is accelerating the development of novel diagnostic solutions. Government support through funding and policy initiatives is driving the expansion of the solid tumor testing market, ensuring that cutting-edge diagnostic technologies become more widely available to patients.
• Integration of AI for Enhanced Diagnostic Accuracy: AI-driven diagnostic tools are playing a critical role in improving the accuracy and efficiency of cancer detection. AI algorithms assist pathologists in analyzing digital pathology slides, reducing diagnostic variability and expediting result turnaround times. The integration of AI in solid tumor testing enhances workflow efficiency, addresses the shortage of pathology specialists, and minimizes diagnostic errors. As AI adoption continues to expand, it will further optimize cancer diagnosis and treatment planning, driving market growth.
Challenges in the solid tumor testing market in Canada are:
• High Costs of Advanced Diagnostic Technologies: Despite advancements in genomic sequencing and liquid biopsy, the high cost of these technologies remains a significant barrier to widespread adoption. Expensive testing procedures limit accessibility, particularly in smaller healthcare facilities. The financial burden on healthcare providers and patients necessitates improved reimbursement frameworks to ensure broader implementation of advanced cancer diagnostics.
• Regulatory Complexities and Approval Delays: The solid tumor testing market is subject to stringent regulatory requirements, which can slow the approval and commercialization of new diagnostic technologies. Navigating the regulatory landscape requires significant time and resources, impacting the speed at which innovations reach the market. Ensuring compliance with evolving health policies remains a challenge for industry stakeholders.
• Shortage of Specialized Healthcare Professionals: The growing demand for molecular diagnostics and AI-driven pathology tools highlights the need for skilled professionals in oncology diagnostics. A shortage of trained pathologists and genomic specialists can hinder the effective implementation of advanced testing technologies, affecting diagnostic accuracy and efficiency.
The Canadian solid tumor testing market is evolving with the rise of precision medicine, genomic sequencing, AI, and government-backed research initiatives. However, challenges such as high costs, regulatory hurdles, and workforce shortages must be addressed to sustain market growth. By overcoming these obstacles, the industry can enhance diagnostic accessibility, improve cancer care, and solidify Canada’s position as a leader in oncology diagnostics.
List of Solid Tumor Testing Market in Canada Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, solid tumor testing companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the solid tumor testing companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10
Solid Tumor Testing Market in Canada by Segment
The study includes a forecast for the solid tumor testing market in Canada by type, application, and end use.
Solid Tumor Testing Market in Canada by Type [Analysis by Value from 2019 to 2031]:
• Genetic Testing
• Conventional Testing
Solid Tumor Testing Market in Canada by Application [Analysis by Value from 2019 to 2031]:
• Prostate
• Breast
• Colorectal
• Endometrial
• Lung
• Melanoma
• Others
Solid Tumor Testing Market in Canada by End Use [Analysis by Value from 2019 to 2031]:
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutions
Features of the Solid Tumor Testing Market in Canada
Market Size Estimates: Solid tumor testing in Canada market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Solid tumor testing in Canada market size by type, application, and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different type, application, and end use for the solid tumor testing in Canada.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the solid tumor testing in Canada.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What are the major drivers influencing the growth of the solid tumor testing market in Canada?
Answer: The major drivers for this market are increase in the utilization of supplements and steroids and increase in unhealthy habits, such as smoking and alcohol consumption.
Q2. What are the major segments for solid tumor testing market in Canada?
Answer: The future of the solid tumor testing market in Canada looks promising with opportunities in the hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions markets.
Q3. Which solid tumor testing market segment in Canada will be the largest in future?
Answer: Lucintel forecasts that melanoma is expected to witness the highest growth over the forecast period due to growing incidence of skin tumors and related conditions globally.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 10 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the solid tumor testing market in Canada by type (genetic testing and conventional testing), application (prostate, breast, colorectal, endometrial, lung, melanoma, and others), and end use (hospitals, pharmaceutical & biotechnology companies, contract research organizations, and academic research institutions)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Solid Tumor Testing Market in Canada, Solid Tumor Testing Market in Canada Size, Solid Tumor Testing Market in Canada Growth, Solid Tumor Testing Market in Canada Analysis, Solid Tumor Testing Market in Canada Report, Solid Tumor Testing Market in Canada Share, Solid Tumor Testing Market in Canada Trends, Solid Tumor Testing Market in Canada Forecast, Solid Tumor Testing Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.